title: The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
abstract: Depression compromises affected individuals' functional well-being and impairs their level of social and workplace performance. Improved social functioning in depressed patients may improve their work productivity. This study evaluated the differential effects of two antidepressants on social functioning outcomes for patients with major depression comparing reboxetine, a non-tricyclic, selective noradrenaline reuptake inhibitor and fluoxetine, a commonly prescribed selective serotonin reuptake inhibitor. A model using data from 284 depressed patients (138 reboxetine, 146 fluoxetine) in two 8-week clinical trials was developed to predict the percentage change over time in continuous outcome assessments as measured by a 21-item self-rating scale called the Social Adaptation Self-evaluation Scale (SASS). The percentage change from baseline SASS score was modelled as a function of both time-invariant and time-varying covariates. Results suggest that, by mid-study, the more severely ill subjects benefitted more from reboxetine treatment in terms of the outcome improvement rate and, by study-end, this effect also extended into the less severely ill population. In addition, a significant relationship was identified between the change in depression symptom severity as measured by the standard Hamilton Depression Rating Scale score and the change in social functioning per the SASS.
authors.affiliation: Analysis Group/Economics, Cambridge, MA 02138, USA.
authors.forename: L N
authors.initials: LN
authors.lastname: Venditti
authors.forename: A
authors.initials: A
authors.lastname: Arcelus
authors.forename: H
authors.initials: H
authors.lastname: Birnbaum
authors.forename: P
authors.initials: P
authors.lastname: Greenberg
authors.forename: C E
authors.initials: CE
authors.lastname: Barr
authors.forename: C
authors.initials: C
authors.lastname: Rowland
authors.forename: T
authors.initials: T
authors.lastname: Williamson
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D012720:Severity of Illness Index; D012919:Social Behavior; D016896:Treatment Outcome
chemical_list: D018759:Adrenergic Uptake Inhibitors; D005473:Fluoxetine; D009025:Morpholines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors